Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regional Coverage

Asia Pacific

Set Alert for Asia Pacific

Latest From Asia Pacific

China Biotech Innovation Reaching Tipping Point?

A rapidly reforming policy and regulatory environment and a growing culture of innovation are encouraging capital and talent to pour into China, making it a question of when, rather than if, the payoffs will come for both consumers and investors.

China Financing

Can Lilly's Olumiant Prickle Xeljanz In India?

Lilly’s Olumiant has hit the Indian market, upping the level of competition in a rheumatoid arthritis sector that already includes the fellow JAK inhibitor Xeljanz from Pfizer and at least half a dozen biosimilar versions of Humira, among other products. But could pricing cloud Olumiant’s uptake?
India Commercial

China Vs. Cancer: Coverage For 17 Drugs Unveils Price Pressures, Commercial Battleground

While cancer drug makers generally applaud the rare reimbursement decision in China, some have pointed to mounting and significant pressure to lower prices, while insiders say the real battle has only just began and that translating the coverage into commercial success will take much more effort.

China Reimbursement

Innovation Ecosystem Needs More Support, BioJapan Hears

Head of industry group in Japan makes personal plea at major biotech meeting for improvements to Japan’s innovation ecosystem, as government representatives say steps are already being taken to improve collaborative research and foster bioventures.

Japan Innovation

Singapore's DotBio Begins Play For Antibody Domain

Emerging Company Profile: Newly formed Singapore venture DotBio aims to develop novel immuno-oncology therapies based on optimized, multi-specific humanized domain antibodies, with a focus on targeting checkpoint blockades, positive immune signals and tumor-specific processes in oncology.

Singapore Biologics

Asia Deal Watch: Alvotech Signs On To Biosimilar Manufacturing JV In China

With partner CCHN, Alvotech will help finance construction of a biologics facility in Changchun, China. Novartis will work with Cellular Biomedicine to produce Kymriah for China, and will gain access to its CAR-T platform.

Deals Commercial
See All

Europe

Set Alert for Europe

Latest From Europe

Sandoz And AbbVie Biosimilar Humira Settlement: What Does It Mean?

Sandoz has become the latest firm to sign a settlement agreement over biosimilar Humira with AbbVie, heralding imminent launch in Europe. In the US, it will hold off launching until September 2023.

Biosimilars Legal Issues

MedinCell Boosts Funding For Long-Acting Injectables Portfolio

France's long-acting injectables technology company, MedinCell, which is collaborating with Teva on a Phase III long-acting risperidone formulation, has completed an IPO on Euronext Paris, giving a lift to its development plans.

 

Neurology Financing

Mundipharma Satisfies Appetite For Piece Of $4.5bn Pegfilgrastim Pie With Cinfa Biotech Buy

Mundipharma widens its biosimilar portfolio by acquiring Cinfa Biotech, and its soon-to-be-launched pegfilgrastim biosimilar.

Biosimilars M & A

Interview: Oryzon Chief Highlights CNS Opportunities

After the setback of Roche pulling the plug on a potentially lucrative cancer partnership last year, the Spanish biotech tells Scrip it has bounced back with a compound that shows potential in Alzheimer's, multiple sclerosis and other neurodegenerative and psychiatric diseases.

Spain Neurology

Parallel Trade Adds Up As Abacus Prepares IPO

With revenues from its parallel trade business climbing 50% year-on-year since 2015, Denmark's Abacus is to seek a listing in Germany to help it keep up with demand.

Financing Distribution

Forbion Attracts New Investors Closing IV Fund At €360M

European life science companies can expect to get access to almost €290m from Forbion as the EU-based venture capitalist closes its fourth fund at an oversubscribed €360m.

Europe Financing
See All

United States

Set Alert for United States

Latest From United States

Industry Makes A Drug Price Transparency Push In DTC Ads, But Is It Too Little Too Late?

PhRMA unveiled a voluntary policy under which drug makers will provide information in DTC ads about how to access drug prices and cost information. But hours later HHS issued a proposed rule on the same topic, only requiring drug makers to include WAC prices in TV ads. .

Pricing Debate Advertising, Marketing & Sales

Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars

The company will not commercialize an insulin glargine copy already tentatively approved by FDA as Lusduna, but says it remains committed to biosimilars in oncology and immunology.

Biosimilars Strategy

Mylan Head Of Biologics Chrys Kokino On Fulphila Launch And US Biosimilars

Mylan's Kokino spoke with Scrip about what he called the successful launch of the company's first biosimilar in the US, a version of Amgen's Neulasta, the state of the US biosimilar market and resetting expectations.

Biosimilars Strategy

Cure Pharmaceutical Targets Rx Entry For Film Strip While Now Focused On Supplements

Cure Pharmaceutical is launching Sleep Stripzzz melatonin supplement delivered in a fast-dissolving oral strip. The company has bigger visions of using the CureFilm delivery method in CBD products and eventually Rx drugs.

Drug Delivery Business Strategies

Momenta Refocuses On Three Novel Autoimmune Drugs In Transition To More Traditional Biotech

Momenta will invest in three novel drugs and end development of all but two late-stage biosimilars under a new business strategy. The company is reducing its workforce by 50%, or about 110 employees.

Business Strategies Companies

Pfizer Launches Nivestym At An Aggressive Discount To Other Filgrastim Products

Pfizer is launching its second US biosimilar, a version of filgrastim, at an aggressive 30.3% discount to Amgen's branded Neupogen and at a discount to competing biosimilars.

 

Biosimilars Launches
See All
Advertisement
UsernamePublicRestriction

Register